Clostridium difficile: Biological therapies

Current Opinion in Infectious Diseases

Volumn 26, Issue 5, 2013, Pages 454-460

  Martin, Jessica ^a,b   Mawer, Damian ^a   Wilcox, Mark H ^a,b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Clostridium difficile; faecal transplant; nontoxigenic; prebiotics; probiotics

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT; FRUCTOSE OLIGOSACCHARIDE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SUCROSE; VANCOMYCIN;

ACTINOBACTERIA; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTEROIDETES; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES MICROFLORA; FIRMICUTES; FOLLOW UP; FUNGAL STRAIN; GRAFT RECIPIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTESTINE FLORA; INTESTINE PERFORATION; LACTOBACILLUS; LACTOBACILLUS INFECTION; LACTOBACILLUS RHAMNOSUS; META ANALYSIS; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; ORGAN DONOR; PATIENT SAFETY; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SACCHAROMYCES BOULARDII; SUSPENSION; SYSTEMATIC REVIEW; TRANSPLANTATION; TREATMENT DURATION;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; PREBIOTICS; PROBIOTICS;

EID: 84883598946     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000433319.82618.8f     Document Type: Review

References (66)

1. Na X, Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol 2011; 45:S154-S158.
2. Lawley TD, Walker AW. Intestinal colonisation resistance. Immunology 2013; 138:1-11.
3. Newton DF, Macfarlane S, Macfarlane GT. Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms. Antimicrob Agent Chemother 2013; 57:2016-2025.
4. Food and Agriculture Organisation of the UN and WHO. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Geneva: World Health Organisation; 2001 ; http://www.who.int/entity/foodsafety/ publications/fs-management/en/probiotics.pdf. [Accessed 20 Mar 2013]
5. Floch MH, Walker A, Madsen K, et al. Recommendations for probiotic use: 2011 update. J Clin Gastroenterol 2011; 45:S168-S171.
6. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009; 9:237-244.
7. Tasteyre A, Barc M, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002; 32:219-225.
8. Trejo FM, Minnaard J, Perez PF, De Antoni GL. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe 2006; 12:186-193.
9. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302-307.
10. Chen X, Kokkotou EG, Mustafa N, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006; 281:24449-24454.
11. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69:2762-2765.
12. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-1918.
13. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-1017.
14. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299 v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a doubleblind, placebo-controlled trial. Scand J Infect Dis 2003; 35:365-367.
15. Plummer S, WeaverMS, Harris JC, et al. Clostridium difficile pilot study: effect of probiotic supplementation on the incidence of Clostridium difficile diarrhoea. Int Microbiol 2004; 7:57-62.
16. Rafiq R, Pandey D, Osman S, et al. Prevention of Clostridium difficile (C. difficile) diarrhoea with probiotics in hospitalized patients treated with antibiotics. Gastroenterology 2007; 132:A187.
17. Gorbach SL, Chang T, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2:1519.
18. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335:80-83.
19. Gao XW, Mubasher M, Fang CT, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adults. Am J Gastroenterol 2010; 105:1636-1641.
20. Pozzoni P, Riva A, Bellatore AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012; 107:922-931.
21. Wilcox MH, Sandoe JA. Probiotics and diarrhoea: data are not widely applicable. BMJ 2007; 335:171.
22. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; CD004611.
23. Tung JM, Dolovich LR, Lee CH. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol 2009; 23:817-821.
24. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012; 7:e34938.
25. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. A systematic review and metaanalysis. JAMA 2012; 307:1959-1969.
26. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med 2012; 157:878-888.
27. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005; 41:1559-1568.
28. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5:290-292.
29. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
30. Public Health England. Updated guidance on the management and treatment of Clostridium difficile infection. Public Health England; 2013; Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317138914904.
31. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010; 16:1661-1665.
32. Allen SJ, Wareham K, Bradley C, et al. A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibioticassociated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis 2012; 12:108.
33. Gibson GR, Probert HM, Van Loo J, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17:259-275.
34. Bouhnik Y, Vahedi K, Achour L, et al. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 1999; 129:113-116.
35. Langlands SJ, Hopkins MJ, Coleman N, Cummings JH. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004; 53:1610-1616.
36. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3:442-448.
37. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351:633-636.
38. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a nontoxigenic strain. Eur J Clin Microbiol 1987; 6:51-53.
39. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with nontoxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agent 2009; 33:S46-S50.
40. Villano S, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agent Chemother 2012; 56:5224-5229.
41. Viropharma. Treatment with VP20621 (Non-Toxigenic Clostridium difficile; NTCD). 2013; Press release. Available at: http://ir.viropharma.com/release detail.cfm?ReleaseID=758059.
42. Eiseman B, Silen W, BascomGS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44:854-859.
43. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-508.
44. Guo B, Harstall C, Louie T, et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile associated disease. Al Pharm and Ther 2012; 35:865-875.
45. Sofi AA, Silcerman AL, Khuder S, et al. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection: pooled data analysis and a systematic review. Scand J Gastroenterol 2013; 48:266-273.
46. Food and Drug Administration. Department of Health and Human Services. Department of Health and Human Services; 2013 ; Available at: http://high roadsolution.com/file-upload-2/files/fda+response+letter+to+fmt+inquiry. pdf.
47. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-1087.
48. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172:191-193.
49. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44:567-570.
50. Jorup-Ronstrom C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhoea in 32 patients. Scan J Gastroenterol 2012; 7:548-552.
51. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (faecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
52. Van Nood E, Vrieze A, NIeuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415.
53. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761-767.
54. Bakken JS, Borody T, Brandt LJ, et al., Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-1049.
55. Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25:255-257.
56. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis, patterns of care and predictors of mortality. JAMA Surg 2009; 144:433-439.
57. Bhangu A, Nepogodiev D, Gupta A, et al. Systematic review and metaanalysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99:1501-1513.
58. Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of faecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55:1652-1658.
59. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1:1156-1160.
60. Mitreva M, The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
61. De Vos WM, de Vos EAJ. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012; 70:S45-S56.
62. Ilseung C, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13:260-270.
63. Huttenhower C. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
64. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8:e1002995.
65. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1:3.
66. VosWM. Fame and future of faecal transplantations: developing next-generation therapies with synthetic microbiomes. Microb Biotech 2013; 6:316-325.